Key result
Serum Gamma Glutamyl Transferase concentration was significantly higher in patients with heart failure due to ischemic heart disease (median 56 U/l) compared to controls without heart failure (34 U/l).
Why the study?
To evaluate serum Gamma Glutamyl Transferase levels across NYHA grades of heart failure due to ischemic heart disease and their relationship with NT-proBNP and ejection fraction.
Does serum Gamma Glutamyl Transferase level correlate with the severity of heart failure in patients with ischemic heart disease?
Cross-Sectional (n=140)
No
Does serum Gamma Glutamyl Transferase level correlate with the severity of heart failure in patients with ischemic heart disease?
Absolute Event Rate: 56% vs 34%
p-value: p=< 0.05
Serum Gamma Glutamyl Transferase levels are significantly elevated in patients with heart failure due to ischemic heart disease and correlate with disease severity, NT-proBNP, and reduced LVEF.
GGT may track ischemic HF severity; hypothesis-generating and requires prospective validation before clinical use.
Purposes: Surveying serum Gamma Glutamyl Transferase levels followed by the grade of heart failure patients (according to the New York Heart Association - NYHA) due to ischemic heart disease and evaluating the relationship between serum Gamma Glutamyl Transferase levels with Heart failure staging and laboratory tests (NT-proBNP levels, (EF) ejection fraction) in heart failure patients due to ischemic heart disease. Method: Study design: a cross - sectional descriptive study, including 140 patients were treated at the Department of Cardiology, Hue Central Hospital, from March 1st, 2021, to May 30th, 2022. They were divided into two groups: the group with heart failure (n = 70) and the control group without heart failure (n = 70). Result: The serum Gamma Glutamyl Transferase concentration increased significantly in the group of patients with heart failure (56 U/l) compared with the control group (34 U/l) (p < 0.05). The median value of serum Gamma Glutamyl Transferase concentrations in heart failure stages II, III, and IV in the study according to NYHA classification was 53 U/l, 56 U/l and 286 U/l, respectively. Serum Gamma Glutamyl Transferase levels were positively correlated with the severity of heart failure according to the NYHA class, (r = 0.49; p < 0.001). GGT had good value in predicting the severity of heart failure (AUC = 0.869; 95% CI: 0.767 - 0.938), the best cutoff GGT ≥ 51 U/l with sensitivity: 81.25%, specificity: 77.27%; Gamma Glutamyl Transferase concentration had a moderate positive correlation with NT-proBNP concentration (r = 0.42; p = 0.0004) and had a negative correlation with left ventricular ejection fraction (LVEF), (r = - 0.3; p = 0.013). Conclusion: With a high diagnostic value, giving fast and accurate results of Gamma Glutamyl Transferase levels in various degrees of chronic heart failure, the Gamma Glutamyl Transferase test should be used as a good support test in the diagnosis and prognosis in patients with heart failure due to ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Thang Doan (2023) conducted a cross-sectional in Heart failure due to ischemic heart disease (n=140). Heart failure due to ischemic heart disease vs. Patients without heart failure was evaluated on Serum Gamma Glutamyl Transferase (GGT) concentration (U/l) (p=< 0.05). Serum Gamma Glutamyl Transferase concentration was significantly higher in patients with heart failure due to ischemic heart disease (median 56 U/l) compared to controls without heart failure (34 U/l).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: